文献速递心胸血管麻醉

绵羊模型下静脉达比加群用于体外循环抗凝研究

Intravenous Dabigatran for Anticoagulation during Cardiopulmonary Bypass in a Sheep Model.
PubMed 文献 · Anesthesiology · 2025-05-27

本研究在绵羊体外循环模型中比较静脉达比加群与肝素抗凝效果及逆转情况。12只绵羊随机分组,CPB 120分钟,监测凝血指标与滤器血栓。达比加群组CPB期间血药浓度低于目标值,但滤器未见血栓,且白介素-6低于肝素组;依达赛珠单抗成功逆转抗凝,5只存活24小时。

要点

  • 达比加群在绵羊CPB模型中提供有效抗凝,动脉滤器未见血栓。
  • CPB期间达比加群血药浓度低于目标值5 µg/ml,范围1.7±0.4至3.4±1.5 µg/ml。
  • 依达赛珠单抗可成功逆转达比加群抗凝效应,5只绵羊存活24小时。

核心结论

  • 达比加群在绵羊CPB模型中有效提供抗凝,依达赛珠单抗能成功逆转其效应。

研究设计与样本

  • 绵羊CPB模型,12只绵羊随机接受静脉达比加群或肝素抗凝(每组6只),行120分钟CPB。
  • 监测活化凝血时间、高岭土/组织因子激活血栓弹力图反应时间及血气,CPB后电镜检动脉滤器血栓。
  • CPB后分别给予依达赛珠单抗或鱼精蛋白逆转,监测24小时,并检测炎症与凝血标志物。

主要发现

  • CPB 120分钟后,达比加群组与肝素组动脉滤器均未见可见血栓或纤维蛋白。
  • CPB期间达比加群血浆浓度低于目标浓度5 µg/ml,范围为1.7±0.4至3.4±1.5 µg/ml。
  • 两组反应时间与活化凝血时间在CPB期间升高,逆转后恢复至接近基线。
  • 肝素组白介素-6浓度高于达比加群组。
  • 依达赛珠单抗给药后5只绵羊存活24小时;鱼精蛋白给药后6只中4只存活24小时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heparin is the standard anticoagulant used during cardiopulmonary bypass (CPB). However, there are problems with heparin, including immunogenicity and variability of effect, that make a search for an alternative desirable. Dabigatran anticoagulation has been reported to provide adequate conditions for CPB in a rabbit model. This study used a sheep model of CPB to assess the efficacy of dabigatran and its reversibility with idarucizumab. METHODS: Twelve sheep were subjected to 120 min of CPB after anticoagulation with either intravenous dabigatran or heparin (N = 6 per group). In both groups, activated clotting time, kaolin/tissue factor-activated thromboelastography reaction time, and blood gases were monitored during and after CPB. Plasma dabigatran concentrations were measured during and after CPB. After CPB, two sections of each arterial filter were examined for thrombus using electron microscopy. Idarucizumab or protamine was administered after CPB to reverse anticoagulation, and the sheep were monitored for a subsequent 24 h. Plasma concentrations of inflammatory and coagulation markers were assessed at baseline, after 120 min of CPB, and 6 h after reversal administration. RESULTS: After 120 min of CPB, there was no visible thrombus or fibrin observed on the arterial line filters in either the dabigatran or heparin groups. Plasma dabigatran concentrations during CPB were below the target concentration (5 µg/ml), ranging from 1.7 ± 0.4 to 3.4 ± 1.5 µg/ml. In both groups, reaction time and activated clotting time values increased during CPB and then returned to nearly baseline levels after administration of the reversal agents. Interleukin-6 concentrations were elevated in the heparin group compared to the dabigatran group. Five sheep survived 24 h after idarucizumab administration. Four of six sheep survived 24 h after the administration of protamine. CONCLUSIONS: This study demonstrates that dabigatran effectively provides anticoagulation in a sheep CPB model, and idarucizumab successfully reverses its effects.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Nadtochiy SM, Stefanos T, Angona RE, et al. Intravenous Dabigatran for Anticoagulation during Cardiopulmonary Bypass in a Sheep Model. Anesthesiology. 2025. PMID: 40424620. doi:10.1097/ALN.0000000000005580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。